Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib Study of APL-1202 in BCG-Resistant NMIBC
NCT03672240Phase 2Completed
- Sponsor
- Asieris Pharmaceuticals
- Start
- Nov 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of APL-1202 + APL-1501 in non-muscle-invasive bladder cancer (NMIBC), sponsored by Asieris Pharmaceuticals. Primary endpoint: Incidence and Severity of Treatment-Related Adverse Events at 13 weeks. Started Nov 2018; status: completed.
02
Drugs
APL-1202 + APL-1501
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT03672240.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03672240.